We Can Medicines Co., Ltd.
Taipei ExchangeTotal Valuation
We Can Medicines Co., Ltd. carries a market capitalization of 1.05B, placing it among publicly traded companies globally. Its enterprise value stands at 2.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.05B |
| Enterprise Value | 2.46B |
Share Statistics
We Can Medicines Co., Ltd. currently has 45.07M shares outstanding.
| Shares Outstanding | 45.07M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.48, and the price-to-book ratio stands at 4.08.
| PE Ratio | N/A |
| PS Ratio | 0.48 |
| PB Ratio | 4.08 |
| P/TBV Ratio | 1.48 |
| P/FCF Ratio | 5.59 |
| P/OCF Ratio | 6.43 |
Enterprise Valuation
| EV / Sales | 0.76 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 8.14 |
Financial Position
We Can Medicines Co., Ltd. maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 114.23, indicating elevated leverage, while an interest coverage ratio of -2.65 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.53 |
| Quick Ratio | 0.30 |
| Debt / Equity | 114.23 |
| Debt / EBITDA | -17.68 |
| Interest Coverage | -2.65 |
Financial Efficiency
| Return on Equity (ROE) | -17.64 |
| Return on Assets (ROA) | -2.41 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.54 |
Taxes
| Income Tax | 18,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
We Can Medicines Co., Ltd.'s stock has declined approximately -34.5021% over the past 52 weeks. The 50-day moving average sits at 26.91, while the 200-day moving average is 30.59.
| Beta (5Y) | N/A |
| 52-Week Price Change | -34.5021% |
| 50-Day Moving Average | 26.91 |
| 200-Day Moving Average | 30.59 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, We Can Medicines Co., Ltd. generated 3.22B in revenue and converted that into -73.21M in net income, yielding earnings per share of -1.63. EBITDA reached -67.72M, while operating income came in at -67.72M.
| Revenue | 3.22B |
| Gross Profit | 1.07B |
| Operating Income | -67.72M |
| Pretax Income | -73.19M |
| Net Income | -73.21M |
| EBITDA | -67.72M |
| EBIT | -67.72M |
| Earnings Per Share (EPS) | -1.63 |
Balance Sheet
We Can Medicines Co., Ltd. holds 285.75M in cash and equivalents against 1.20B in total debt, resulting in a net debt position of -104.47M. Total book value stands at 378.68M, with working capital of 501.81M providing operational flexibility.
| Cash & Cash Equivalents | 285.75M |
| Total Debt | 1.20B |
| Net Debt | -104.47M |
| Equity (Book Value) | 378.68M |
| Book Value Per Share | 8.44 |
| Working Capital | 501.81M |
Cash Flow
We Can Medicines Co., Ltd. produced 240.02M in operating cash flow over the past twelve months. After subtracting -35.92M in capital expenditures, free cash flow totaled 204.10M - equivalent to 4.55 per share.
| Operating Cash Flow | 240.02M |
| Capital Expenditures | -35.92M |
| Free Cash Flow | 204.10M |
| FCF Per Share | 4.55 |
Margins
We Can Medicines Co., Ltd. operates with a gross margin of 33.15, reflecting its pricing power and cost economics. The operating margin of -2.10 and net profit margin of -2.27 provide insight into operational efficiency.
| Gross Margin | 33.15 |
| Operating Margin | -2.10 |
| Pretax Margin | -2.27 |
| Profit Margin | -2.27 |
| EBITDA Margin | -2.10 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 17.23 |
| FCF Yield | 17.88 |
Scores
We Can Medicines Co., Ltd. posts an Altman Z-Score of 1.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.66 |